DOCSLIB.ORG

Transcription Profile of HTLV-I-Infected Cells Compared to Activated Lymphocytes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transcription Profile of HTLV-I-Infected Cells Compared to Activated Lymphocytes Transcription Profile of HTLV-I-Infected Cells Compared to Activated Lymphocytes Cynthia A. Pise-Masison1, Michael Radonovich1, Renaud Mahieux2, Pramita Chatterjee1, Craig Whiteford3, Janet Duvall1, Claire Guillerm1, Antoine Gessain2, and John N. Brady1* 1Basic Research Laboratory, Virus Tumor Biology Section, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, 2Unite d'Epidemiologie et Physiopathologie des Virus Oncogenes, Batiment SIDA-Retrovirus, 28, rue du Dr Roux, Institut Pasteur, 75724 Paris cedex 15, 3ATC, National Institutes of Health, Gaithersburg, MD, 20805 *Corresponding Author: [email protected]; tel.:(301)496-0986; fax.:(301)496-4951 [email protected]; tel: (301)435-2499; fax: (301)496-4951 [email protected]; tel: (301)496-4953;fax: (301)496-4951 [email protected]; tel: (33)-1-45-68-89-06;fax: (33)-1- 40-61-34-65 [email protected]; tel: (301)496-4793;fax: (301)496-4951 [email protected]; tel: (301)402-9217;fax: (301)496-4951 [email protected]; tel: (301)435-2501; fax: (301)496-4951 [email protected]; tel: (301)496-0988;fax: (301)496-4951 [email protected]; tel: (33)-1-45-68-89-06;fax: (33)-1- 40-61-34-65 Running title: Gene Expression Profiles of HTLV-I-Infected Cells Key Words: HTLV-I, ATL, Transcription, Microarray, Gene Expression 1 Supplementary Table. A list of the 763 differentially expressed genes in the HTLV-I-infected cells compared to activated donor peripheral blood lymphocytes (PBLs), listed by category. All genes listed were expressed either 2-fold or greater (increased) or 2-fold or less (decreased) in comparison to activated PBLs. Indicated by gray shading, genes already identified as differentially expressed in microarray studies are listed. GenBank Acc. No. Gene Description Citationa Harhaj de La Ruckes et.al. Fuente et.al. et. al. Increased Genes Transcription factors AD000092_cds7_s_at AF005887_at (ATF6) CREB binding serum response factor D14826_s_at (CREM) cAMP responsive element modulator D87673_at (HSF4) heat shock transcription factor 4 D90070_s_at (APR) PMA induced mRNA D90224_at (TNFSF4) tumor necrosis factor (ligand) superfamily up up gp34 J04076_at early growth response 2 (Krox-20 homolog) up J04102_at ETS2 up J04111_at c-Jun up L19871_at (ATF3) activating transcription factor 3 L23587_at DP-1 up L34587_at putative gene up L37936_at elongation factor Ts L40386_s_at DP-2 L46353_at HMG1-C M16038_at Lyn M37583_at (H2AFZ) M57732_at transcription factor 1, hepatic; LF-B1, HNF1 M61156_at (TFAP2A) transcription factor AP-2 alpha M62810_at transcription factor 6-like 1 up M69043_at (NFKBIA) IKB alpha M74719_at (TCF4) transcription factor 4 M77810_at GATA-2 up M92357_at B94 up S73205_at (INSAF) insulin activator factor U15460_at B-ATF U20734_s_at JunB up U24166_at EB1 U51127_at (IRF5) interferon regulatory factor 5 U52682_at (IRF4) interferon regulatory factor 4 U59863_at (I-TRAF) U91616_at (NFKBIE) cytoplasmic NFkB inhibitor epsilon Receptors/Signaling molecules 2 D26070_at (ITPR1) inositol 1,4,5-triphosphate receptor, type 1 D38076_at (RANBP1) D38128_at (PTGIR) prostaglandin I2 (prostacyclin) receptor (IP) D49489_at The transcript is amplified in hydroxyurea-resistant cells D50678_at (LRP8) low density lipoprotein receptor-related protein 8 J03258_at (VDR) vitamin D (1,25- dihydroxyvitamin D3) receptor K02405_f_at prepeptide MHC HLA-DC3-beta L08069_at (HSJ2) heat shock protein DNAJ-like 2 L08096_at (TNFSF7) CD27 ligand up L08187_at (EBI3) up L08488_at (INPP1) inositol polyphosphate-1-phosphatase L12723_at (HSPA4) heat shock 70kD protein 4 L13740_at TR3 orphan receptor L19872_at (AHR) aryl hydrocarbon receptor L38608_at (ALCAM) CD6 ligand L40357_at (TRIP7) thyroid hormone receptor interactor 7 L40379_at (TRIP10) thyroid receptor interacting protein 10 L77886_at (PTPRK) protein tyrosine phosphatase, receptor type, K M11058_at (HMGCR)3-hydroxy-3-methylglutaryl-Coenzyme A reductase M11749_at Thy-1 glycoprotein M16276_at (HLA-DQB1) MHC, class II, DQ beta 1 M16441_cds1_ (TNF) tumor necrosis factor (TNF superfamily, member 2) at M22382_at (HSPD1) heat shock protein 60kDa up M23197_at (CD33) M24283_at (ICAM1) intercellular adhesion molecule 1 (CD54) up M26958_at (PTHrP) M33600_f_at (HLA-DRB5) M34996_at cell surface glycoprotein class II M35128_at (CHRM1) cholinergic receptor, muscarinic 1 M57466_s_at (HLA-DPB1) MHC, class II, DP beta 1 M59465_at (A20) TNFAIP1 M62424_at (F2R) coagulation factor II receptor up M83554_at (TNFRSF8) TNF receptor superfamily, member 8 up CD30 M83664_at (HLA-DPB1) MHC, class II, DP beta 1 M83738_at (PTPN9) protein tyrosine phosphatase, non-receptor type 9 M84349_at (CD59) U03398_at (TNFSF9) ILA ligand (TNF related) U07550_at (HSPE1) heat shock protein 10kDa U10550_at (gem) GTPase U12767_at (MINOR) U29343_at (HMMR) hyaluronan-mediated motility receptor (RHAMM) U31628_at (IL15RA) interleukin 15 receptor, alpha U33017_at (SLAM) signaling lymphocytic activation molecule U37546_s_at (API1) apoptosis inhibitor 1 U45983_at (CCR8) U64198_at (IL12RB2) interleukin 12 receptor, beta 2 U68030_at (CCR6) up U70426_at (RGS16) regulator of G-protein signalling 16 U72761_at (KPNB3) beta 3 karyopherin (importin) 3 X00274_at (HLA-DRA) up X01057_at (IL2RA) interleukin 2 receptor, alpha up up X01060_at (TFRC) transferrin receptor (p90, CD71) up X02317_at (SOD1) superoxide dismutase up up X02419_rna1_a (PLAU) plasminogen activator, urokinase t X02530_at (INP1-) IFN-induced protein down X02910_at TNF alpha down X03068_f_at precursor class II antigen X03100_cds2_ (HLA-SB) MHC, class II antigen beta at X62744_at (HLA-DM) MHC, class II, DM alpha X77584_at (TXN) thioredoxin Y00636_at (CD58) Z97074_at Rab9 effector GTPase p40 up Kinases/Phosphatases AB003698_at (CDC7L1) D10495_at (1-May) Protein Kinase C delta up up D10522_at (MACS) MARCKS, 80K-L up J02902_at protein phosphatase 2A regulatory alpha subunit L08488_at (INPP1) inositol polyphosphate-1-phosphatase L08835_rna2_a (DMPK) dystrophia myotonica-protein kinase t L11329_at (DUSP2) dual specificity phosphatase 2 up L20320_at (CDK7) cyclin-dependent kinase 7 L37043_at (CSNK1E) casein kinase 1, epsilon L76927_rna1_a (GALK1) galactokinase 1 t L77886_at (PTPRK) protein tyrosine phosphatase, receptor type, K M68520_at (CDK2) cyclin-dependent kinase 2 M80359_at (MARK3) MAP/microtubule affinity-regulating kinase 3 U15932_at (DUSP5) dual specificity phosphatase 5 up U37022_rna1_a (CDK4) cyclin-dependent kinase 4 t U43522_at (PTK2B) protein tyrosine kinase 2 beta U48296_at (PTP4A1) protein tyrosine phosphatase type IVA, member 1 U48807_at (DUSP4) dual specificity phosphatase 4 U59919_at (SMAP) Smg GDS-associated protein X02419_rna1_a (PLAU) plasminogen activator, urokinase t X17620_at (NME1) non-metastatic cells 1, protein (NM23A) X54941_at (CKS1) CDC28 protein kinase 1 X54942_at (CKS2) CDC28 protein kinase 2 X56468_at 14.3.3 protein tau X56494_at (PKM2) pyruvate kinase, muscle X89416_at (PPP5) Y00815_at (PTPRF) protein tyrosine phosphatase, receptor type, F Y07604_at (NME4) non-metastatic cells 4 Y10275_at (PSP) phosphoserine phosphatase Z18951_at (CAV1) caveolin 1, caveolae protein, 22kD Cytokines/interleukins/oncogenes 4 D43767_at (SCYA17) small inducible cytokine subfamily A (Cys- up Cys) J00219_at (IFNG) interferon gamma up J04156_at (IL7) interleukin 7 L00058_at c-myc protein, second translated L08187_at (EBI3) cytokine receptor up M13207_at (CSF2) GM-CSF M13755_at (ISG15) IFN-induced 15kDa protein up M14745_at bcl-2 protein up M26062_at (IL2RB) interleukin 2 receptor, beta M28130_at (IL8) interleukin 8 M28209_at (RAB1) RAB1, member RAS oncogene family M28215_at (RAB5A) GTP-binding protein up M30135_at (P40) T-cell and mast cell growth factor precursor M37435_at (CSF1) M57506_rna1_ (SCYA1) I-309 up up up at M57731_at (GRO3) GRO3 oncogene M59941_at (CSF2RB) GM-CSF receptor beta chain M65291_at (IL12A) interleukin 12 A U01038_at (pLK) polo-like kinase up U03397_at (TNFRSF9) ILA U11877_at (IL8RB) interleukin 8 receptor beta U14407_at (IL15) interleukin 15 U31120_rna1_a (IL13) interleukin 13 up t U31628_at (IL15RA) interleukin 15 receptor, alpha U64198_at (IL12RB2) interleukin 12 receptor, beta 2 U83171_at (SCYA22) small inducible cytokine subfamily A (Cys-Cys) X01057_at (IL2RA) interleukin 2 receptor, alpha up up X04602_s_at (IL6) interleukin 6 (interferon, beta 2) up X12794_at (ERBAL2) v-erb-a X51345_at (JUNB) jun B proto-oncogene up 681_s_at (JUND) jun D proto-oncogene X58298 (IL6R) interleukin 6 receptor X67951_at (PAGA) proliferation-associated gene A X75042_at (REL) v-rel avian reticuloendotheliosis viral oncogene up up homolog Y00081_s_at BSF-2/IL6 gene Y10659_at (IL13RA1) interleukin 13 receptor alpha 1 Cell cycle/apoptosis/repair AF005775_at (CFLAR) CASP8 and FADD-like apoptosis regulator D00017_at (ANX2) annexin II D13639 cyclin D2 up up D14878_at (D123) D123 gene product S-phase entry regulator up D21063_at (MCM2) minichromosome maintenance deficient 2 (mitotin) D55716 (P1cdc47) MCM7 D84557_at (HsMcm6) J04611_at (G22P1) 70kDa KU autoantigen J05614_at PCNA L07493_at (RPA3) replication factor 5 L07541_at (RFC3) replication factor 3 up L20320_at (CDK7) cyclin-dependent kinase 7 L25876_at (CIP2) associated with cyclin-dependent kinase M15796_at PCNA M16441_cds1_ (TNF) tumor necrosis factor (TNF superfamily, down at member 2) M17754_at (BN51T) BN51 (BHK21) M25753_at cyclin B1 up up M34065_at (CDC25C) cell division cycle 25C M36089_at (MSH2) X-ray repair complementing defective repair protein up M60974 GADD45 up up M68520_at (CDK2) cyclin-dependent 2 M74093_at (CCNE1) cyclin E1 M87339_at
Load more

Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • SUPPLEMENTARY DATA Supplementary Tables Table S1
    1 SUPPLEMENTARY DATA 2 3 Supplementary Tables 4 Table S1. Gene signatures Gene signature Genes Cytolytic GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 Cytotoxic CD8+ T cells CD8A, GZMA, GZMB, IFNG, EOMES, PRF1 Activated CD4+ T cells CD4, IL2RA, CD69 CD4+ Treg cells FOXP3, CTLA4, ICOS Immune checkpoints—T cells BTLA, LAG3, HAVCR2, PDCD1, TIGIT, CTLA4 T cells CD2, CD3D, CD3E, CD3G, CD6, TRAT1, CD28, LCK B cells CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NK cells SLAMF7, KLRC3, KLRK1, KLRC2, KLRD1 Monocytes CD14, CD16, CD163, CSF1R, HLA-DR LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, M2 macrophages PTPRC, SLA, SEPSECS, MSR1, FPR3, FCGR2A, FCGR3A, IDO1, RERE, ABL2, CD163L1, STAT3, SBNO2, CSF1, CSF2 FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL12a1, Active fibroblasts COL5A1, COL8A2, THY1, PALLD Antigen processing TAPBP, TAP1, TAP2, PSMB9, PSMB8 Immune checkpoints—APC CD274, PDCD1LG2, IDO1 Costimulatory ligands CD40, CD80, CD86, CD70, TNFRSF18 CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, Costimulatory receptors TNFSF14, CD226 Myeloid inflammation CCL2, IL1B, CXCL8, IL6, PTGS2 1 DERL1, DERL2, DNAJB11, DNAJB9, DNAJC10, DNAJC3, ER stress EDEM1, EDEM2, EDEM3, EIF2AK3, ERO1L, HERPUD1, PDIA3, PDIA6, SEC61A1, SERP1, SYVN1 RRM2, UBE2C, BIRC5, CEP55, CCNB1, NUF2, NDC80, Proliferation MKI67, CDC20, TYMS 5 ER, endoplasmic reticulum; NK, natural killer. 6 7 2 8 Table S2. Most common all-cause and treatment-related AEs Patients (N = 45) All cause Treatment related Eventa Any grade Grade 3/4 Any grade Grade 3/4 Any AE 45 (100.0) 20 (44.4)
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Silencing of Phosphoinositide-Specific
    ANTICANCER RESEARCH 34: 4069-4076 (2014) Silencing of Phosphoinositide-specific Phospholipase C ε Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines VINCENZA RITA LO VASCO1, MARTINA LEOPIZZI2, DANIELA STOPPOLONI3 and CARLO DELLA ROCCA2 Departments of 1Sense Organs , 2Medicine and Surgery Sciences and Biotechnologies and 3Biochemistry Sciences “A. Rossi Fanelli”, Sapienza University, Rome, Italy Abstract. Background: Ezrin, a member of the signal transduction pathway (5). The reduction of PIP2 ezrin–radixin–moesin family, is involved in the metastatic induces ezrin dissociation from the plasma membrane (6). spread of osteosarcoma. Ezrin binds phosphatydil inositol-4,5- The levels of PIP2 are regulated by the PI-specific bisphosphate (PIP2), a crucial molecule of the phospholipase C (PI-PLC) family (7), constituting thirteen phosphoinositide signal transduction pathway. PIP2 levels are enzymes divided into six sub-families on the basis of amino regulated by phosphoinositide-specific phospholipase C (PI- acid sequence, domain structure, mechanism of recruitment PLC) enzymes. PI-PLCε isoform, a well-characterized direct and tissue distribution (7-15). PI-PLCε, a direct effector of effector of rat sarcoma (RAS), is at a unique convergence RAS (14-15), might be the point of convergence for the point for the broad range of signaling pathways that promote broad range of signalling pathways that promote the RAS GTPase-mediated signalling. Materials and Methods. By RASGTPase-mediated signalling (16). using molecular biology methods and microscopic analyses, In previous studies, we suggested a relationship between we analyzed the expression of ezrin and PLC genes after PI-PLC expression and ezrin (17-18).
    [Show full text]
  • ALCAM Regulates Mediolateral Retinotopic Mapping in the Superior Colliculus
    15630 • The Journal of Neuroscience, December 16, 2009 • 29(50):15630–15641 Development/Plasticity/Repair ALCAM Regulates Mediolateral Retinotopic Mapping in the Superior Colliculus Mona Buhusi,1 Galina P. Demyanenko,1 Karry M. Jannie,2 Jasbir Dalal,1 Eli P. B. Darnell,1 Joshua A. Weiner,2 and Patricia F. Maness1 1Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, and 2Department of Biology, University of Iowa, Iowa City, Iowa 52242 ALCAM [activated leukocyte cell adhesion molecule (BEN/SC-1/DM-GRASP)] is a transmembrane recognition molecule of the Ig superfamily (IgSF) containing five Ig domains (two V-type, three C2-type). Although broadly expressed in the nervous and immune systems, few of its developmental functions have been elucidated. Because ALCAM has been suggested to interact with the IgSF adhesion molecule L1, a determi- nant of retinocollicular mapping, we hypothesized that ALCAM might direct topographic targeting to the superior colliculus (SC) by serving as a substrate within the SC for L1 on incoming retinal ganglion cell (RGC) axons. ALCAM was expressed in the SC during RGC axon targeting and on RGC axons as they formed the optic nerve; however, it was downregulated distally on RGC axons as they entered the SC. Axon tracing with DiI revealedpronouncedmistargetingofRGCaxonsfromthetemporalretinahalfofALCAMnullmicetoabnormallylateralsitesinthecontralateral SC, in which these axons formed multiple ectopic termination zones. ALCAM null mutant axons were
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • Β-Catenin Knockdown Affects Mitochondrial Biogenesis and Lipid Metabolism in Breast Cancer Cells
    ORIGINAL RESEARCH published: 27 July 2017 doi: 10.3389/fphys.2017.00544 β-Catenin Knockdown Affects Mitochondrial Biogenesis and Lipid Metabolism in Breast Cancer Cells Daniele Vergara 1, 2 †, Eleonora Stanca 1, 2 †, Flora Guerra 1, Paola Priore 3, Antonio Gaballo 3, Julien Franck 4, Pasquale Simeone 5, Marco Trerotola 6, Stefania De Domenico 7, Isabelle Fournier 4, Cecilia Bucci 1, Michel Salzet 4, Anna M. Giudetti 1* and Michele Maffia 1, 2* 1 Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy, 2 Laboratory of Clinical Proteomic, “Giovanni Paolo II” Hospital, Lecce, Italy, 3 CNR NANOTEC - Institute of Nanotechnology, Lecce, Italy, 4 University of Lille, Institut national de la santé et de la recherche médicale, U-1192 - Laboratoire Protéomique, Réponse Edited by: Inflammatoire et Spectrométrie de Masse-PRISM, Lille, France, 5 Unit of Cytomorphology, CeSI-MeT and Department of Andrei Surguchov, Medicine and Aging Sciences, School of Medicine and Health Sciences, University “G. d’Annunzio,” Chieti, Italy, 6 Unit of Kansas University of Medical Center Cancer Pathology, CeSI-MeT and Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio,” Research Institute, United States Chieti, Italy, 7 C.N.R. Unit of Lecce, Institute of Food Production Sciences, Lecce, Italy Reviewed by: Kamal Datta, β-catenin plays an important role as regulatory hub in several cellular processes including Georgetown University, United States Silvana Gaetani, cell adhesion, metabolism, and epithelial mesenchymal transition. This is mainly achieved Sapienza Università di Roma, Italy by its dual role as structural component of cadherin-based adherens junctions, and as Clizia Chinello, University of Milano-Bicocca, Italy a key nuclear effector of the Wnt pathway.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Pro-Inflammatory Tnfα and IL-1Β Differentially Regulate the Inflammatory Phenotype of Brain Microvascular Endothelial Cells Simon J
    O’Carroll et al. Journal of Neuroinflammation (2015) 12:131 JOURNAL OF DOI 10.1186/s12974-015-0346-0 NEUROINFLAMMATION RESEARCH Open Access Pro-inflammatory TNFα and IL-1β differentially regulate the inflammatory phenotype of brain microvascular endothelial cells Simon J. O’Carroll1,2, Dan Ting Kho1,3, Rachael Wiltshire1, Vicky Nelson1,3, Odunayo Rotimi1,2, Rebecca Johnson1,3, Catherine E. Angel4 and E. Scott Graham1,3* Abstract Background: The vasculature of the brain is composed of endothelial cells, pericytes and astrocytic processes. The endothelial cells are the critical interface between the blood and the CNS parenchyma and are a critical component of the blood-brain barrier (BBB). These cells are innately programmed to respond to a myriad of inflammatory cytokines or other danger signals. IL-1β and TNFα are well recognised pro-inflammatory mediators, and here, we provide compelling evidence that they regulate the function and immune response profile of human cerebral microvascular endothelial cells (hCMVECs) differentially. Methods: We used xCELLigence biosensor technology, which revealed global differences in the endothelial response between IL-1β and TNFα. xCELLigence is a label-free impedance-based biosensor, which is ideal for acute or long-term comparison of drug effects on cell behaviour. In addition, flow cytometry and multiplex cytokine arrays were used to show differences in the inflammatory responses from the endothelial cells. Results: Extensive cytokine-secretion profiling and cell-surface immune phenotyping confirmed that the immune response of the hCMVEC to IL-1β was different to that of TNFα. Interestingly, of the 38 cytokines, chemokines and growth factors measured by cytometric bead array, the endothelial cells secreted only 13.
    [Show full text]
  • Downloaded in Aug 2019
    ARTICLE https://doi.org/10.1038/s41467-021-24473-2 OPEN IL-15 and PIM kinases direct the metabolic programming of intestinal intraepithelial lymphocytes Olivia J. James1, Maud Vandereyken1, Julia M. Marchingo 2, Francois Singh1, Susan E. Bray3, Jamie Wilson4, ✉ Andrew G. Love1 & Mahima Swamy 1 1234567890():,; Intestinal intraepithelial lymphocytes (IEL) are an abundant population of tissue-resident T cells that protect and maintain the intestinal barrier. IEL respond to epithelial cell-derived IL-15, which is complexed to the IL-15 receptor α chain (IL-15/Rα). IL-15 is essential both for maintaining IEL homeostasis and inducing IEL responses to epithelial stress, which has been associated with Coeliac disease. Here, we apply quantitative mass spectrometry to IL-15/Rα- stimulated IEL to investigate how IL-15 directly regulates inflammatory functions of IEL. IL-15/ Rα drives IEL activation through cell cycle regulation, upregulation of metabolic machinery and expression of a select repertoire of cell surface receptors. IL-15/Rα selectively upregu- lates the Ser/Thr kinases PIM1 and PIM2, which are essential for IEL to proliferate, grow and upregulate granzyme B in response to inflammatory IL-15. Notably, IEL from patients with Coeliac disease have high PIM expression. Together, these data indicate PIM kinases as important effectors of IEL responses to inflammatory IL-15. 1 MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK. 2 Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK. 3 NHS Research Scotland, Tayside Tissue Biorepository, University of Dundee, Dundee, UK. 4 Department of ✉ Pathology, NHS Tayside, Ninewells Hospital, Dundee, UK.
    [Show full text]
  • Regulation of Canonical Wnt Signalling by the Ciliopathy Protein MKS1 and the E2
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.08.897959; this version posted March 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Regulation of canonical Wnt signalling by the ciliopathy protein MKS1 and the E2 ubiquitin-conjugating enzyme UBE2E1. Katarzyna Szymanska1, Karsten Boldt2, Clare V. Logan1, Matthew Adams1, Philip A. Robinson1+, Marius Ueffing2, Elton Zeqiraj3, Gabrielle Wheway1,4#, Colin A. Johnson1#* *corresponding author: [email protected] ORCID: 0000-0002-2979-8234 # joint last authors + deceased 1 Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK 2 Institute of Ophthalmic Research, Center for Ophthalmology, University of Tübingen, Tübingen, Germany 3 Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK 4 Faculty of Medicine, University of Southampton, Human Development and Health, UK; University Hospital Southampton NHS Foundation Trust, UK 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.01.08.897959; this version posted March 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract A functional primary cilium is essential for normal and regulated signalling. Primary ciliary defects cause a group of developmental conditions known as ciliopathies, but the precise mechanisms of signal regulation by the cilium remain unclear.
    [Show full text]